Last reviewed 2026-04-23 · How we verify

PAx5/PCMx5

SWOG Cancer Research Network · Phase 3 active Small molecule

PAx5/PCMx5 is a Multi-agent chemotherapy regimen Small molecule drug developed by SWOG Cancer Research Network. It is currently in Phase 3 development for Hematologic malignancies (specific indication dependent on SWOG trial protocol). Also known as: Lansoprazole: Prevacid.

PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies.

PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies. Used for Hematologic malignancies (specific indication dependent on SWOG trial protocol).

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PAx5/PCMx5
Also known as	Lansoprazole: Prevacid
Sponsor	SWOG Cancer Research Network
Drug class	Multi-agent chemotherapy regimen
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

This is a multi-agent chemotherapy combination protocol used in cancer treatment. The exact composition and mechanism depend on the specific SWOG trial design, but typically involves cytotoxic agents that work through DNA damage and cell cycle disruption. PAx5/PCMx5 represents a standardized treatment regimen evaluated in phase 3 clinical trials.

Approved indications

Hematologic malignancies (specific indication dependent on SWOG trial protocol)

Common side effects

Myelosuppression
Nausea and vomiting
Alopecia
Infection risk
Cardiotoxicity

Key clinical trials

S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PAx5/PCMx5 CI brief — competitive landscape report
PAx5/PCMx5 updates RSS · CI watch RSS
SWOG Cancer Research Network portfolio CI

Frequently asked questions about PAx5/PCMx5

What is PAx5/PCMx5?

PAx5/PCMx5 is a Multi-agent chemotherapy regimen drug developed by SWOG Cancer Research Network, indicated for Hematologic malignancies (specific indication dependent on SWOG trial protocol).

How does PAx5/PCMx5 work?

PAx5/PCMx5 is a chemotherapy regimen combining prednisone, doxorubicin, cyclophosphamide, and other agents designed to treat hematologic malignancies.

What is PAx5/PCMx5 used for?

PAx5/PCMx5 is indicated for Hematologic malignancies (specific indication dependent on SWOG trial protocol).

Who makes PAx5/PCMx5?

PAx5/PCMx5 is developed by SWOG Cancer Research Network (see full SWOG Cancer Research Network pipeline at /company/swog-cancer-research-network).

Is PAx5/PCMx5 also known as anything else?

PAx5/PCMx5 is also known as Lansoprazole: Prevacid.

What drug class is PAx5/PCMx5 in?

PAx5/PCMx5 belongs to the Multi-agent chemotherapy regimen class. See all Multi-agent chemotherapy regimen drugs at /class/multi-agent-chemotherapy-regimen.

What development phase is PAx5/PCMx5 in?

PAx5/PCMx5 is in Phase 3.

What are the side effects of PAx5/PCMx5?

Common side effects of PAx5/PCMx5 include Myelosuppression, Nausea and vomiting, Alopecia, Infection risk, Cardiotoxicity.

Drug class: All Multi-agent chemotherapy regimen drugs
Manufacturer: SWOG Cancer Research Network — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Hematologic malignancies (specific indication dependent on SWOG trial protocol)
Also known as: Lansoprazole: Prevacid

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing